0001193125-26-047737
SEC filingBenitec Biopharma Inc. reported a net loss of $11.8 million for Q2 2026 (period ending December 31, 2025), with no revenue generated during the quarter. The company incurred total operating expenses of $13.4 million, primarily driven by research and development costs of $5.8 million and general and administrative expenses of $7.5 million. This resulted in an operating loss of $13.4 million, partially offset by total other income of $1.5 million, mainly from interest income of $1.4 million. The company's cash position strengthened significantly with a net increase of $91.0 million in cash, cash equivalents, and restricted cash, reaching $97.9 million at period end, largely due to $104.5 million in proceeds from common stock issuance. Total assets stood at $190.7 million with stockholders' equity of $187.4 million, while total liabilities remained low at $3.3 million.
Benitec Biopharma Inc. reported financial results for Q2 2026 (period ending December 31, 2025) showing continued development-stage operations with no revenue generation. The company recorded a net loss of $11.8 million, consistent with its pre-revenue biopharmaceutical status. Operating loss was $13.4 million, driven by research and development expenses of $5.8 million and general and administrative expenses of $7.5 million. The loss was partially mitigated by other income of $1.5 million, primarily from interest income of $1.4 million. Total comprehensive loss was $12.0 million, including an unrealized foreign currency translation loss of $133K. The company's cash position improved significantly during the quarter with a net increase of $91.0 million in cash, cash equivalents, and restricted cash.
No revenue was generated during Q2 2026, as indicated by total revenues of $0 in the income statement. The company remains in the development stage with its gene therapy pipeline and has not yet commercialized any products. The document provides no segment breakdown or geographic revenue mix, as the company operates as a single segment focused on developing DNA-directed RNA interference-based therapeutics. No revenue growth drivers or product sales are disclosed in the filing.
With zero revenue, gross margin and operating margin calculations are not applicable. The company's cost structure shows research and development expenses of $5.8 million and general and administrative expenses of $7.5 million for the quarter. Share-based compensation expense was significant at $12.6 million, though this is a non-cash item. The operating loss margin cannot be calculated as a percentage of revenue due to the absence of revenue. The net loss margin similarly cannot be expressed as a percentage.
Net cash used in operating activities was $7.1 million for the quarter, primarily driven by the net loss of $11.8 million adjusted for non-cash items including share-based compensation of $12.6 million. Investing activities used $11K for property and equipment purchases. Financing activities provided $98.2 million net cash, mainly from $104.5 million in proceeds from common stock issuance, offset by $6.3 million in share issuance costs. The balance sheet shows strong liquidity with total current assets of $189.6 million, including cash and cash equivalents of $188.8 million. Total assets were $190.7 million with minimal liabilities of $3.3 million, resulting in stockholders' equity of $187.4 million. The company has no debt disclosed in the filing.
The filing does not contain specific management guidance, forward-looking statements, or explicit strategic priorities for future periods. No revenue projections, earnings guidance, or specific clinical development milestones are provided in the document content. The company's continued operations as a development-stage biopharmaceutical company suggest ongoing research and development activities, but no quantitative outlook or risk factor updates beyond the standard disclosures typically found in SEC filings are presented in this specific 10-Q submission.